Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone

被引：0
|
作者：
Harousseau, J. L.
Nagler, A.
Sonneveld, P.
Blade, J.
Hajek, R.
Spencer, A.
Robak, T.
Xiu, L.
Zhuang, S. H.
Orlowski, R. Z.
机构：
[1] Hoteldieu Hosp, Nantes, France
[2] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[3] Erasmus MC, Rotterdam, Netherlands
[4] Hosp Clin I Prov, Barcelona, Spain
[5] Interni Hematoonkol Klin Fak Brno, Brno, Czech Republic
[6] Alfred Hosp, Melbourne, Vic, Australia
[7] Med Univ Lodz, Lodz, Poland
[8] Johnson & Johnson PRD, Raritan, NJ USA
[9] Univ N Carolina, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8002
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma:: Combination therapy improves time to progression
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Hajek, Roman
    Spencer, Andrew
    Miguel, Jesus San
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander N.
    Zhuang, Sen H.
    Parekh, Trilok
    Xiu, Liang
    Yuan, Zhilong
    Rackoff, Wayne
    Harousseau, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3892 - 3901
  • [2] Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander N.
    Xiu, Liang
    Cakana, Andrew
    Parekh, Trilok
    San-Miguel, Jesus F.
    CANCER, 2016, 122 (13) : 2050 - 2056
  • [3] Pegylated liposomal doxorubicin and bortezomib in relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (07): : 453 - 455
  • [4] Effect of disease stage and time since diagnosis on time to progression for pegylated liposomal doxorubicin plus bortezomib vs bortezomib alone in relapsed or refractory multiple myeloma
    Sutherland, Heather J.
    Blade, Joan
    Miguel, Jesus San
    Nagler, Amon
    Sonneveld, Pieter
    Spencer, Andrew
    Robak, Tadeusz
    O'Neal, Wane
    Mundle, Sudeel D.
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    BLOOD, 2007, 110 (11) : 805A - 805A
  • [5] Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma
    Orlowski, Robert Z.
    Nagler, Arnon
    Sonneveld, Pieter
    Blade, Joan
    Hajek, Roman
    Spencer, Andrew
    Robak, Tadeusz
    Dmoszynska, Anna
    Horvath, Noemi
    Spicka, Ivan
    Sutherland, Heather J.
    Suvorov, Alexander
    Xiu, Liang
    Parekh, Trilok V.
    San Miguel, Jesus
    BLOOD, 2014, 124 (21)
  • [6] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [7] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
  • [8] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [9] The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase III study.
    Orlowski, Robert Z.
    Zhuang, Sen H.
    Parekh, Trilok
    Xiu, Liang
    Harousseau, Jean-Luc
    BLOOD, 2006, 108 (11) : 124A - 124A
  • [10] Bortezomib, liposomal doxorubicin and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma
    Falcone, A.
    Sanpaolo, G.
    Bodenizza, C.
    Carella, A. M.
    Dell'Olio, M.
    Mantuano, S.
    Melillo, L.
    Merla, E.
    Scalzulli, F.
    Cascavilla, N.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 148
12345